Severity
Moderate
FDA Drug recall · Reported February 8, 2023
CGMP deviations
Discovery Pharma LLC recalled Conzerol zero molluscum contagiosum, Homeopathic treatment for Molluscum Contagiosum, Top… - a moderate-severity action.
Conzerol zero molluscum contagiosum, Homeopathic treatment for Molluscum Contagiosum, Top… was recalled by Discovery Pharma LLC in February 8, 2023. Reason: CGMP deviations. Check the official notice for the remedy. Verify recall #D-0261-2023 with the FDA Drug before acting.
The recall
Discovery Pharma LLC issued this moderate-severity FDA Drug recall-CGMP deviations.
Sourced from official FDA Drug enforcement records. Verify recall #D-0261-2023 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0261-2023) was formally reported on February 8, 2023, with the manufacturer initiating the action on November 9, 2022. It is classified under Moderate severity (Class II), with a current status of Terminated. Discovery Pharma LLC is listed as the recalling firm, operating out of Oviedo, FL. Federal records list the affected scope as 21,892 tubes.
The documented reason for this recall is: CGMP deviations Distribution data in the federal record shows the product reached: CA, FL, WA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 3 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 1,360 cosmetics & personal care recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
21,892 tubes
Related Recalls
6
3 from same agency
Conzerol zero molluscum contagiosum, Homeopathic treatment for Molluscum Contagiosum, Topical Cream, Net weight 0.78 oz (22g) tube, UPC 8 60322 00180 8, Manufactured by: Dr. Retter EC Warszawska 17, 05-075 Warszawa Poland
CGMP deviations
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0261-2023 |
| Date reported | February 8, 2023 |
| Date initiated | November 9, 2022 |
| Recalling firm | Discovery Pharma LLC |
| Firm location | Oviedo, FL |
| Affected scope | 21,892 tubes |
| Distribution | CA, FL, WA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
· 2026-06-04
PS Seasoning & Spices, Inc. · 2026-05-27
Fontana Flavors, Inc · 2026-05-27
Wisconsin Pharmacal Company · 2026-05-27
SUN PHARMACEUTICAL INDUSTRIES INC · 2026-04-22
Compare this recall with Tiny Land Children's Play Tents Recalled Due to Risk of Inj… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported February 8, 2023. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.